Human adenovirus type 35: nucleotide sequence and vector development.
about
Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunizationCircumventing antivector immunity: potential use of nonhuman adenoviral vectorsProduction of adenovirus vectors and their use as a delivery system for influenza vaccines.A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice.Yeast Surface-Displayed H5N1 Avian Influenza Vaccines.Characterization of human adenovirus 35 and derivation of complex vectorsDesmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.Potent Antitumor Activity Generated by a Novel Tumor Specific Cytotoxic T Cell.Human Adenovirus Serotype 3 Vector Packaged by a Rare Serotype 14 HexonTherapeutic potential of adenovirus as a vaccine vector for chronic virus infections.T-cell immunity generated by recombinant adenovirus vaccines.Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States.Adenoviral producer cellsApplying genomic and bioinformatic resources to human adenovirus genomes for use in vaccine development and for applications in vector development for gene delivery.The revolution in viral genomics as exemplified by the bioinformatic analysis of human adenoviruses.Transduction of liver metastases after intravenous injection of Ad5/35 or Ad35 vectors with and without factor X-binding protein pretreatmentGetting genetic access to natural adenovirus genomes to explore vector diversity.Genome size and structure determine efficiency of postinternalization steps and gene transfer of capsid-modified adenovirus vectors in a cell-type-specific manner.Adenoviruses use lactoferrin as a bridge for CAR-independent binding to and infection of epithelial cells.Development and assessment of human adenovirus type 11 as a gene transfer vector.Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobsAnalysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectorsTherapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck.Transposon-assisted cloning and traceless mutagenesis of adenoviruses: Development of a novel vector based on species D.Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities.The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p).Adenovirus serotype 35 vector-mediated transduction following direct administration into organs of nonhuman primates.Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV.Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys.Adenovirus 5- and 35-based immunotherapy enhances the strength but not breadth or quality of immunity during chronic SIV infection.
P2860
Q24538818-DF06ECC7-A2C0-4EE7-B22A-9A7E1F987DFFQ26995655-3BA0CED4-DE5D-488A-A3F4-C45075112B9CQ30226988-2FBADBDF-1672-4267-86AD-0F62B97FB92BQ30389068-A6EF977C-19A1-410D-83C2-6779C8F7E5DBQ30397351-475B8FC9-7697-4927-A0D1-EA6C5063A968Q34322336-7E57D49A-A7EF-403B-BAC9-CAA93F0DD993Q34781681-37DFDA6B-9F20-404D-AF77-9D84429417DCQ34794162-7FE10714-C83A-4F54-93C2-ECAC62C22E1AQ36058021-597363EF-6A02-4756-B3CB-0AB361E049BCQ36349567-D6FD2CD8-F801-47CA-A67B-1C25C3B3BABBQ36837129-DF75B059-0448-4E3C-81CF-05C8017A38E9Q37015368-BB0B38B6-DB67-446B-AF72-2854CC9F8DE6Q37945217-3CA66F7B-0C72-4F0B-A56E-F6C2AB7E7AD8Q38613979-11934B9B-178C-4344-9566-F6EA977C9E4EQ38615517-0EDE166C-86CB-4C7B-BC97-12E5B254EE01Q39278465-8A024AB9-8982-4608-A312-96524E69E4E2Q39437315-46F8C2EC-6051-4EFB-9DEC-692E7B8B3E80Q39960246-61E3D467-1023-442A-8083-B2CDB8AEDEC4Q40213253-17B92EE8-1C73-4C8B-913D-6E887D2A29A7Q40441928-0080A165-1670-4BE2-809F-6843048F3C60Q40722127-F808983F-1308-47D9-B2A3-113D70E60CA7Q40815226-B2175C12-AB2E-47B5-9AA8-346B32E28285Q41218508-F0FA1BB8-AF83-4F07-8605-116C75086B88Q41900379-BE79E216-DD15-48D0-A2C3-6BE0869ED417Q44957854-79E43108-0037-4669-97FC-F25EEF7BD637Q45856648-71FBF9AA-0523-4BBB-8727-9C5B8C847B5CQ45880369-00DBF72F-DA01-4416-BB62-2C1E2771FF7FQ45885655-F33726C1-1CEF-45EC-83FB-285FF7F781ABQ45888470-8A03588E-5B56-4EE9-8EDF-752322AFC8A2Q51891172-65AA3894-5EF6-4251-A415-D8B8CC7BB1A4
P2860
Human adenovirus type 35: nucleotide sequence and vector development.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Human adenovirus type 35: nucleotide sequence and vector development.
@en
type
label
Human adenovirus type 35: nucleotide sequence and vector development.
@en
prefLabel
Human adenovirus type 35: nucleotide sequence and vector development.
@en
P2093
P2860
P356
P1433
P1476
Human adenovirus type 35: nucleotide sequence and vector development.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.GT.3302097
P577
2003-11-01T00:00:00Z
P5875
P6179
1050339567